AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00528567
Drug: Standard adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
Trial: NCT02754765
Drug: Control arm MDR-TB regimen, consistent with WHO guidelines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm MDR-TB regimen, consistent WHO guidelines
Trial: NCT01963793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel without active component
Trial: NCT00916201
Drug: URB597
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg / d for 5 days, orally
Trial: NCT02521831
Drug: Spinal Anesthesia (bupivacaine)
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.
Trial: NCT00912444
Drug: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
Trial: NCT00912444
Drug: Docetaxel, cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
Trial: NCT02496572
Drug: Short course MDR-TB treatment regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration.
Trial: NCT04552262
Drug: BAY2327949
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 90 mg BAY2327949
Trial: NCT04552262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo to BAY 2327949
Trial: NCT03484260
Drug: Testosterone Product
RxNorm normalized name: testosterone Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men used testosterone product following prescription
Trial: NCT03762915
Drug: minocycline HCl microspheres
RxNorm normalized name: minocycline HCl microspheres
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
Trial: NCT04645550
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Trial: NCT01219959
Drug: Dianeal
RxNorm normalized name: Dianeal PD-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
Trial: NCT01219959
Drug: Dianeal, Extraneal, Nutrineal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
Trial: NCT04682431
Drug: PY159 Single agent dose level 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Trial: NCT04682431
Drug: PY159 Single agent dose expansion cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of PY159 as a single agent given for predefined tumor histology
Trial: NCT01665573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acquisition of conditioning Administration of placebo Extinction of conditioning
Trial: NCT00276731
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04715386
Drug: StrataXRT
RxNorm normalized name: Strataxrt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.
Trial: NCT01678924
Drug: AGN-214868
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-214868 given as injections into the area of pain on Day 1.
Trial: NCT03232749
Drug: corticosteroid injections
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid will be administered is used to treat pain and swelling that occurs with arthritis and other joint disorder
Trial: NCT03844620
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT02433535
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
Trial: NCT03232905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as tablet
Trial: NCT02056574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01566474
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
Trial: NCT02156466
Drug: MSB0010841
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Trial: NCT02156466
Drug: MSB0010841
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Trial: NCT02156466
Drug: MSB0010841
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Trial: NCT02156466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Trial: NCT00881621
Drug: Lapatinib and Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
Trial: NCT03151967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal applicator with medium containing no drug
Trial: NCT01706679
Drug: Placebo vehicle (PBS)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01858558
Drug: No aMIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
Trial: NCT04090684
Drug: Fixed dose combination Ciprofloxacin/Celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
Trial: NCT00293475
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IA
Trial: NCT02010970
Drug: Group 1 AZD3293
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3293 oral solution
Trial: NCT02010970
Drug: Group 2 AZD3293
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3293 oral solution
Trial: NCT02010970
Drug: Group 3 AZD3293
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3293 oral solution
Trial: NCT04250311
Drug: MMH-407
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMH-407: For oral use.
Trial: NCT04250311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: For oral use.
Trial: NCT00546832
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02737436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
Trial: NCT00731432
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical in shape and texture to treatment patch
Trial: NCT04516564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo is administered via intravenous infusion to healthy subjects
Trial: NCT01598415
Drug: SAR113945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Trial: NCT01598415
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Trial: NCT03131908
Drug: GSK2636771
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.~Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I.
Trial: NCT04567173
Drug: Anti-SARS-CoV-2 convalescent plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19
Trial: NCT02962531
Drug: IX-01 caplets 1600 mg (4 x 400 mg), fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose under fasted conditions
Trial: NCT00569231
Drug: Candida Antigen
RxNorm normalized name: Candida antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
Trial: NCT00623116
Drug: Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
Trial: NCT01314911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
Trial: NCT04213573
Drug: MI Varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical fluoride varnish with calcium and phosphate
Trial: NCT00908063
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
Trial: NCT04060888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ustekinumab IV or SC.
Trial: NCT03748524
Drug: Influenza Vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza Vaccine,Quadrivalent SIngle vaccination all participants at day 0
Trial: NCT00700310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
Trial: NCT00400946
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01814501
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously. A bolus of 400 mg/m2 to be followed by a continuous infusion over 46 hrs at a dose of 2400mg/m2.
Trial: NCT01814501
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin will be administered at a dose of 200 mg/m2 over 120 minutes prior to the 5-FU bolus. Leucovorin may be run simultaneously with irinotecan infusion via y-site connection.
Trial: NCT02279823
Drug: CB-03-01 solution
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug solution
Trial: NCT02279823
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle solution
Trial: NCT00400946
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00400946
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02414854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Trial: NCT02414854
Drug: Inhaled corticosteroid (ICS) therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
Trial: NCT00400946
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00400946
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04397354
Drug: No additional drugs(control Group)
RxNorm normalized name: Heparin group antithrombotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: No drugs will be injected middle ear with cochlear implantation
Trial: NCT00400946
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00400946
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01190098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
Trial: NCT03293511
Drug: intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 IU of of placebo nasal spray will be applied to each subject.
Trial: NCT00398489
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02957682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04622865
Drug: Best Supportive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs or biologics drugs.
Trial: NCT01357031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
Trial: NCT00008554
Drug: GW433908
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00176852
Drug: Busulfan, Cyclophosphamide, ATG, GCSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC \>2500 x 2 days.
Trial: NCT04208581
Drug: Yiqi Huoxue Huatan granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
Trial: NCT04208581
Drug: Placebo Yiqi Huoxue Huatan granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
Trial: NCT00023192
Drug: T-Cell Depleted & CD34+Select/w/StemCell Enriched Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01982864
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure.~Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance...).~The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD).
Trial: NCT01501201
Drug: optimized medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
Trial: NCT00501826
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03129256
Drug: Apatinib Mesylate tablet combined with S-1 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use with low-dose Apatinib combined with S-1 until disease progression
Trial: NCT00501826
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04360655
Drug: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
Trial: NCT00501826
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00501826
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and PO
Trial: NCT01259518
Drug: TRIN2755
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
Trial: NCT00174239
Drug: controlled-release levodopa / carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00139646
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01187849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers will be given Metformin or placebo for 1 month, once daily
Trial: NCT01461057
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
Trial: NCT00866749
Drug: Intrathecal Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
Trial: NCT00866749
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting Dose 1g/m2 by vein in weeks 1 and 5
Trial: NCT00866749
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting Dose 60 mg/m2 by mouth on days 1-14 of each month